Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies

S. C. Gulati, C. Shimazaki, R. M. Lemoli, J. Atzpodien, B. D. Clarkso n

Research output: Contribution to journalArticle

Abstract

To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 μmol/l. Under similar conditions, approximately 1 % of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various kpurging methods for myeloma cells for autologous bone marrow transplantation.

Original languageEnglish
Pages (from-to)164-172
Number of pages9
JournalEuropean Journal of Haematology, Supplement
Volume43
Issue number51
Publication statusPublished - 1989

Fingerprint

perfosfamide
Lymphokine-Activated Killer Cells
Etoposide
Bone Marrow Cells
Cell Line
Granulocyte-Macrophage Progenitor Cells
Antibodies
Autologous Transplantation
Lymphoma
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

Gulati, S. C., Shimazaki, C., Lemoli, R. M., Atzpodien, J., & Clarkso n, B. D. (1989). Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. European Journal of Haematology, Supplement, 43(51), 164-172.

Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. / Gulati, S. C.; Shimazaki, C.; Lemoli, R. M.; Atzpodien, J.; Clarkso n, B. D.

In: European Journal of Haematology, Supplement, Vol. 43, No. 51, 1989, p. 164-172.

Research output: Contribution to journalArticle

Gulati, SC, Shimazaki, C, Lemoli, RM, Atzpodien, J & Clarkso n, BD 1989, 'Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies', European Journal of Haematology, Supplement, vol. 43, no. 51, pp. 164-172.
Gulati, S. C. ; Shimazaki, C. ; Lemoli, R. M. ; Atzpodien, J. ; Clarkso n, B. D. / Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. In: European Journal of Haematology, Supplement. 1989 ; Vol. 43, No. 51. pp. 164-172.
@article{4b2a148135cc43e5b85617a9cf8ed171,
title = "Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies",
abstract = "To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 μmol/l. Under similar conditions, approximately 1 {\%} of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various kpurging methods for myeloma cells for autologous bone marrow transplantation.",
author = "Gulati, {S. C.} and C. Shimazaki and Lemoli, {R. M.} and J. Atzpodien and {Clarkso n}, {B. D.}",
year = "1989",
language = "English",
volume = "43",
pages = "164--172",
journal = "Scandinavian journal of haematology. Supplementum",
issn = "0902-4506",
publisher = "Wiley-Blackwell",
number = "51",

}

TY - JOUR

T1 - Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies

AU - Gulati, S. C.

AU - Shimazaki, C.

AU - Lemoli, R. M.

AU - Atzpodien, J.

AU - Clarkso n, B. D.

PY - 1989

Y1 - 1989

N2 - To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 μmol/l. Under similar conditions, approximately 1 % of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various kpurging methods for myeloma cells for autologous bone marrow transplantation.

AB - To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) cells were treated at different concentrations of 4-HC, VP-16. In separate experiments, LAK cells or antibodies were also used to treat the above cell lines. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal bone marrow cells at a 4-HC concentration of 60 μmol/l. Under similar conditions, approximately 1 % of normal BM myeloid progenitor granulocyte-macrophage colony forming cells (CFU-GM) survived. The results with LAK cells and antibodies were also encouraging. These observations support the use of various kpurging methods for myeloma cells for autologous bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0024935106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024935106&partnerID=8YFLogxK

M3 - Article

C2 - 2627987

AN - SCOPUS:0024935106

VL - 43

SP - 164

EP - 172

JO - Scandinavian journal of haematology. Supplementum

JF - Scandinavian journal of haematology. Supplementum

SN - 0902-4506

IS - 51

ER -